A. Egan

发表

Aotus New World monkeys: model for studying malaria-induced anemia.

D. Kaslow, A. Saul, L. Miller, 2002, Blood.

parasite growth in vitro . merozoite surface protein 1 do not inhibit module in the Plasmodium falciparum recognize the first epidermal growth factor-like Naturally acquired human antibodies

A. Holder, E. Riley, P. Druilhe, 2022 .

Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum

A. Holder, D. Kaslow, E. Riley, 1995, Infection and immunity.

Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds

A. Holder, E. Riley, M. Pinder, 1997, Infection and immunity.

Human immune responses to the C-terminus of the malaria vaccine candidate antigen, the major merozoite surface protein of Plasmodium falciparum (PfMSP1)

A. Egan, 1995 .

Immunogenicity and Efficacy in Aotus Monkeys of Four Recombinant Plasmodium falciparum Vaccines in Multiple Adjuvant Formulations Based on the 19-Kilodalton C Terminus of Merozoite Surface Protein 1

M. Blackman, D. Kaslow, Sanjai Kumar, 2000, Infection and Immunity.

Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection

A. Holder, E. Riley, R. Richards, 1996, Infection and immunity.

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.

A. Holder, B. Greenwood, D. Kaslow, 1996, The Journal of infectious diseases.

Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting.

E. Riley, A. Jepson, R. Taylor, 1996, International immunology.

Vaccine Efficacy of Recombinant Plasmodium falciparumMerozoite Surface Protein 1 in Malaria-Naive, -Exposed, and/or -Rechallenged Aotus vociferans Monkeys

M. Blackman, D. Kaslow, A. Egan, 2000, Infection and Immunity.

Human antibodies to the 19 kDa C‐terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro

A. Holder, E. Riley, P. Druilhe, 1999, Parasite immunology.

Naturally acquired human antibodies which recognize the first epidermal growth factor-like module in the Plasmodium falciparum merozoite surface protein 1 do not inhibit parasite growth in vitro

A. Holder, E. Riley, P. Druilhe, 1994, Infection and immunity.

Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid.

B. F. Hall, W. Keitel, D. Kaslow, 1999, Vaccine.